Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOW: Semaglutide vs placebo for renal outcomes in type 2 diabetes with chronic kidney disease
jRCT2080224766Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Semaglutide 1.0 mg with Placebo (2 arms). Primary endpoint: Composite kidney event (first occurrence). Started Jul 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080224766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224766.